Background
==========

Breast cancer is a heterogeneous disease for which several forms have recently been identified on the basis of their gene expression characteristics \[[@B1]\]. We have previously demonstrated that protein expression characteristics can be used to identify comparable classes \[[@B2]\]. In the present study we extend this approach using improved biostatistical methods to confirm the validity of such an approach and to further define the key criteria for class membership.

Methods
=======

Expression of 25 proteins, with known relevance to breast cancer, have been assessed in a series of 1,076 patients. This large dataset has been examined by four alternative computational data clustering techniques. Concordance between techniques was used to elucidate core classes of patients that could be well characterised.

Results
=======

A total of 663/1,076 (62%) patients were assigned to six different core classes, while 413 (38%) patients were of indeterminate or mixed class. Three of these core classes correspond to well known clinical phenotypes (luminal A, luminal B and HER2). Two classes correspond to the well known basal phenotype, but exhibit a novel differentiation into two subgroups. The last class appears to characterise a novel luminal subgroup.

Conclusion
==========

The present study serves to confirm that key clinical phenotypes of breast cancer can be identified. It has identified that both the luminal and basal breast cancer phenotypes appear to be heterogeneous and contain distinct subgroups. Of importance is the observation that only 62% of breast cancer cases in this cohort have been assigned to the determined phenotypes, while the remaining 38% of cases express mixed or indeterminate characteristics. This latter observation, although previously recognised, has not been emphasised in the past. It has important clinical implications should either cDNA expression or protein expression assays be used for stratification of patients into treatment groups either in clinical trails or for routine clinical management. The clinical phenotypes determined in this study are a new luminal group, luminal N, the new basal subgroups, basal X and basal Y, and the previously well-established luminal A, luminal B and HER2 groups.
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